Experienced in Pure Red Cell Aplasia

Silverio Perrotta

Naples, IT 
Experienced in Pure Red Cell Aplasia
Naples, IT 
OverviewLocationsClinical Research

Overview

Silverio Perrotta practices in Naples, Italy. Mr. Perrotta is rated as an Experienced expert by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Beta Thalassemia, Anemia, Hemolytic Anemia, Thalassemia, and Splenectomy.

His clinical research consists of co-authoring 167 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Pure Red Cell Aplasia.

Gender
Male

Locations

Naples, Italy
Other Locations
Italy
Caserta, Italy
Turin, Italy
Milan, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2024
Intervention Type: Drug
View 3 Less Clinical Trials

167 Total Publications

Thalassemia-Associated mixed hypogonadism (TAMH): unraveling a unique endocrine pattern and its impact on cardiovascular risk.
Thalassemia-Associated mixed hypogonadism (TAMH): unraveling a unique endocrine pattern and its impact on cardiovascular risk.
Journal: Endocrine
Published: July 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Perrotta's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 62 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile